173 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF 98. Miyazaki S, Miyauchi K, Hayashi H, Yamashiro K, Tanaka R, Nishizaki Y, et al. Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry. J Cardiol. 2022;80:41–8. 99. Pisters R, van Vugt S, Brouwer M, Elvan A, ten Holt W, Zwart P, et al. Real-life use of rivaroxaban in the Netherlands: data from the Xarelto for prevention of stroke in patients with atrial fibrillation (XANTUS) registry. Neth Heart J. 2017;25(10):551–8. 100.Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda Y, Kitazawa H, et al. The impact of cancer on major bleeding and stroke/systemic emboli in patients using direct oral anticoagulants: from the database of a single-center registry. J Atr Fibrillation. 2018;11(4):2105. 101. Sato T, Aizawa Y, Kitazawa H, Okabe M. The characteristics and clinical outcomes of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: from the database of a single-center registry. J Atr Fibrillation. 2020;13(2):1–8. 102.Suwa M, Morii I, Kino M. Rivaroxaban or apixaban for non-valvular atrial fibrillation: efficacy and safety of off-label under-dosing according to plasma concentration. Circ J. 2019;83(5):991–9. 103. Tedders KM, Lucey MF, Edwin SB. Evaluation of pharmacist-managed dabigatran in an inpatient setting. Ann Pharmacother. 2013;47(12):1649–53. 104.Tellor K, Patel S, Armbruster A, Daly M. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther. 2015;40(4):447–51. 105.Tran TH, Nguyen C, Lam T, Campbell P. Bleeding incidence and real-life prescribing practices with dabigatran use in an acute care setting. Consult Pharm. 2014;29(11):735–40. 106.Umei M, Kishi M, Sato T, Shindo A, Toyoda M, Yokoyama M, et al. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm. 2017;33(5):475–82. 107. Vinding NE, Staerk L, Gislason GH, Torp-Pedersen C, Bonde AN, Rørth R, et al. Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. Eur Heart J Cardiovasc Pharmacother. 2021;7(1):20–30. 108.Xing LY, Barcella CA, Sindet-Pedersen C, Bonde AN, Gislason GH, Olesen JB. Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a Danish nationwide cohort study. Thromb Res. 2019;178:101–9. 109.Yiginer O, Tezcan M, Erdal E, Degirmencioglu G, Acar G, Ergelen M, et al. A real-world, retrospective, observational study of dabigatran and rivaroxaban in Turkey: elderly patients receive inappropriately low dose of rivaroxaban. Int J Clin Exp Med. 2017;10(7):10634–42. 110. Zeymer U, Lober C, Wolf A, Richard F, Schäfer H, Taggeselle J, et al. Use, persistence, efficacy, and safety of apixaban in patients with non-valvular atrial fibrillation in unselected patients in Germany: results of the prospective apixaban in atrial fibrillation (APAF) registry. Cardiol Ther. 2020;9(2):467–78. 111. Abe I, Takahashi N. Wait a minute to prescribe off-label reduced dose of apixaban. Eur Heart J Cardiovasc Pharmacother. 2021;7:424–5. 112. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–604. 113. Ueda A, Toki S, Kitayama C, Akazawa M. Reduction in the doses of direct oral anticoagulants and risk of ischemic stroke events: a hospital survey. Biol Pharm Bull. 2020;43(7):1135–40. 114.Arbel R, Sergienko R, Hammerman A, Greenberg-Dotan S, Batat E, Avnery O, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med. 2019;132(7):847-55.e3. 8
RkJQdWJsaXNoZXIy MTk4NDMw